Calgary, Alberta — November 5, 2025 — Leads & Copy — Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) has announced encouraging one-month results from all patients in Group 1 of its first-in-human clinical study evaluating the Ocumetics Accommodating Intraocular Lens (the “Ocumetics Lens”).
The company completed Group 1 surgeries in August and September 2025. All Group 1 patients have now completed their one-month postoperative exams, showing Corrected Distance Visual Acuity (CDVA) ranging from 20/32 to 20/25.
According to Dean Burns, President and CEO of Ocumetics, the visual outcomes have met, and in some cases, exceeded internal expectations at this early stage of recovery. He added that every Group 1 patient is showing steady improvement with visual acuity and that these results strongly reinforce the company’s belief in the transformative potential of the Ocumetics Lens.
Dr. Doyle Stulting, Chief Medical Officer of Ocumetics, said that achieving 20/32 or better vision this soon after surgery is remarkable and gives the company great confidence as it advances to the next patient groups.
The primary objectives of Group 1 were to confirm safety, evaluate surgical technique, and assess distance vision restoration. The results to date demonstrate that the Ocumetics Lens performs as designed providing safe implantation and strong optical performance.
Planning for Group 2 surgeries is now underway, with updates to follow in the coming weeks.
For further information, please contact Dave Burwell, Director, Investor Relations at dave.burwell@ocumetics.com or (403) 410-7907.
Source: Ocumetics Technology Corp.
